Cell Expansion Market Report 2026

The cell expansion market size has grown rapidly in recent years. It will grow from $32.31 billion in 2025 to $37.54 billion in 2026 at a compound annual growth rate (CAGR) of 16.2%. The growth in the historic period can be attributed to expansion of biopharmaceutical manufacturing, rising use of mammalian cell cultures, adoption of cell expansion in vaccine production, growth of research-scale cell cultivation, availability of disposable culture systems.

The cell expansion market size is expected to see rapid growth in the next few years. It will grow to $69.42 billion in 2030 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period can be attributed to increasing demand for cell and gene therapies, rising investments in large-scale biologics production, expansion of regenerative medicine pipelines, growing focus on cost-efficient scale-up, increasing adoption of closed-system expansion technologies. Major trends in the forecast period include increasing adoption of single-use cell expansion systems, rising demand for scalable cell culture platforms, growing use of serum-free expansion media, expansion of automated bioreactor systems, enhanced focus on process standardization.

Rising government investment in research and development is anticipated to drive the growth of the cell expansion market in the coming years. Government funding refers to financial support provided by public authorities to support specific initiatives or objectives. Increased government spending on research and development in cell expansion plays a crucial role in encouraging innovation, advancing cell-based therapies, and accelerating progress in regenerative medicine. For instance, in September 2023, the National Cancer Institute, a US-based government agency, received a budget allocation of $7.3 billion from the United States Congress for fiscal year 2023, representing an increase of $408 million compared to 2022. Therefore, rising government funding for research and development is fueling the growth of the cell expansion market.

Leading companies operating in the cell expansion market are focusing on advances in bioprocessing technologies, such as automated three-dimensional (3D) bioreactor systems, to improve the efficiency and scalability of cell production for therapeutic uses. PluriCDMO delivers large-scale, automated cell therapy manufacturing through its proprietary 3D bioreactor platform, enabling consistent and high-quality output from early-stage development through clinical trials. For instance, in January 2024, Pluristem Therapeutics Inc., an Israel-based biotechnology firm, introduced a new business unit called PluriCDMO to provide cell therapy manufacturing services as a contract development and manufacturing organization (CDMO). This division features a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Through this initiative, Pluristem will offer services spanning early preclinical development to late-stage clinical trials and commercialization.

In March 2023, Sartorius AG, a Germany-based pharmaceutical company, acquired Polyplus-Transfection SA for $2.36 billion. This acquisition is intended to strengthen Sartorius AG’s support for cell and gene therapy companies by expanding its portfolio in gene therapies and gene-modified cell therapies. Polyplus-Transfection SA is a France-based biotechnology company that provides solutions for gene and cell therapy, biologics manufacturing, and life science research.

Major companies operating in the cell expansion market are Thermo Fisher Scientific Inc., Becton Dickinson and Company, Lonza Group, Corning Inc., Merck KGaA, Sartorius Stedim Biotech SA, Terumo Corporation, Miltenyi Biotec GmbH, Danaher Corporation, Stemcell Technologies Inc., Beckman Coulter Inc., Takara Bio Inc., RepliCel Life Sciences, Neximmune Inc., Celltainer Biotech BV, GE HealthCare Technologies Inc., ReproCELL USA Inc., iXCells Biotechnologies Inc., Neuromics LLC, G&G Technologies Inc., Eppendorf AG, Avantor Inc., Bio-Techne Corporation, BioLife Solutions Inc., Cesca Therapeutics Inc., Core Dynamics Ltd., Lifeline Scientific Inc., Princeton Cryotech Inc., VWR International LLC, Azenta US Inc., MVE Biological Solutions LLC, BioCision LLC, BioSpherix Ltd.

North America was the largest region in the cell expansion market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell expansion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell expansion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cell expansion market by increasing costs of imported bioreactors, culture media, single-use consumables, sensors, and process control systems. Biopharmaceutical companies in North America and Europe are most affected due to dependence on imported manufacturing equipment, while Asia-Pacific faces higher costs for scale-up infrastructure. These tariffs are increasing production expenses and delaying capacity expansion. However, they are also supporting local manufacturing of consumables, regional bioprocess equipment production, and supply chain localization.

The cell expansion market research report is one of a series of new reports that provides cell expansion market statistics, including cell expansion industry global market size, regional shares, competitors with a cell expansion market share, detailed cell expansion market segments, market trends and opportunities, and any further data you may need to thrive in the cell expansion industry. This cell expansion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell expansion refers to a cellular process involved in generating new cell wall material. Its function is to regulate the loosening of the cell wall, allowing it to stretch and enlarge in specific regions. Cell wall-associated proteins belonging to the expansin family play a critical role in facilitating this process.

The main types of cell expansion include mammalian, microbial, and others. Mammalian cell expansion is used for growing cells derived from mammals and involves culturing these cells in flasks or bioreactors under in vitro conditions. The products used in this process include consumables, reagents, media, serums, disposables, and instruments, which are applied across areas such as biopharmaceuticals, tissue culture and engineering, vaccine production, drug development, gene therapy, cancer research, stem cell research, and others. It is utilized by biopharmaceutical and biotechnology companies, research institutes, cell banks, and other end users.

The cell expansion market includes revenues earned by entities by providing bioreactors and automated cell expansion systems. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.